tetano
Editor, Senior Moderator
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Apr 3;43(0):E040. doi: 10.3760/cma.j.cn112147-20200311-00312. [Epub ahead of print]
[Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019].
[Article in Chinese; Abstract available in Chinese from the publisher]
Zhang T[SUP]1[/SUP], Sun LX[SUP]2[/SUP], Feng RE[SUP]3[/SUP].
Author information
Abstract
in English, Chinese
Severe acute respiratory syndrome (SARS) and coronavirus disease 2019 (COVID-19) shared similar pathogenetic, clinical and pathological features. Fever and cough were the most common symptoms of both diseases, while myalgia and diarrhea were less common in patients with COVID-19. Acute respiratory distress syndrome (ARDS) was the most severe pulmonary complication that caused high mortality rate. Histologically, diffuse alveolar damage (DAD) was the most characteristic finding in non-survivors with either SARS or COVID-19. Cases of patients died less than 10~14 days of disease duration demonstrated acute-phase DAD, while cases beyond 10~14 days of disease duration exhibited organizing-phase DAD in SARS. Meanwhile, organization and fibrosis were usually accompanied by exudation. Coronavirus was mostly detected in pneumocytes, while less in macrophages and bronchiolar epithelial cells. Hemorrhagic necrosis and lymphocytes depletion were found in lymph nodes and spleen in both SARS and COVID-19, indicating a pathological basis of lymphocytopenia. Thrombosis was commonly observed in small vessels and microvascular in lungs accompanying DAD. Microthrombosis was also found in extrapulmonary organs in COVID-19, that was less reported in SARS. Damages in multiple extrapulmonary organs were observed, but coronavirus was not detected in some of those organs, might indicating an alternative mechanism beyond viral infection, such as hypoxemia, ischemia and cytokine storm induced immunological injury. Diffuse alveolar damage due to viral infection and immunological injury, as well as multi-organ dysfunction and extensive microthrombus formation, brought huge challenge to the management of patients with severe SARS or COVID-19.
KEYWORDS:
Coronavirus disease 2019; Diffuse alveolar damage; Pathology; Severe acute respiratory syndrome
PMID:32241072DOI:10.3760/cma.j.cn112147-20200311-00312
[Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019].
[Article in Chinese; Abstract available in Chinese from the publisher]
Zhang T[SUP]1[/SUP], Sun LX[SUP]2[/SUP], Feng RE[SUP]3[/SUP].
Author information
Abstract
in English, Chinese
Severe acute respiratory syndrome (SARS) and coronavirus disease 2019 (COVID-19) shared similar pathogenetic, clinical and pathological features. Fever and cough were the most common symptoms of both diseases, while myalgia and diarrhea were less common in patients with COVID-19. Acute respiratory distress syndrome (ARDS) was the most severe pulmonary complication that caused high mortality rate. Histologically, diffuse alveolar damage (DAD) was the most characteristic finding in non-survivors with either SARS or COVID-19. Cases of patients died less than 10~14 days of disease duration demonstrated acute-phase DAD, while cases beyond 10~14 days of disease duration exhibited organizing-phase DAD in SARS. Meanwhile, organization and fibrosis were usually accompanied by exudation. Coronavirus was mostly detected in pneumocytes, while less in macrophages and bronchiolar epithelial cells. Hemorrhagic necrosis and lymphocytes depletion were found in lymph nodes and spleen in both SARS and COVID-19, indicating a pathological basis of lymphocytopenia. Thrombosis was commonly observed in small vessels and microvascular in lungs accompanying DAD. Microthrombosis was also found in extrapulmonary organs in COVID-19, that was less reported in SARS. Damages in multiple extrapulmonary organs were observed, but coronavirus was not detected in some of those organs, might indicating an alternative mechanism beyond viral infection, such as hypoxemia, ischemia and cytokine storm induced immunological injury. Diffuse alveolar damage due to viral infection and immunological injury, as well as multi-organ dysfunction and extensive microthrombus formation, brought huge challenge to the management of patients with severe SARS or COVID-19.
KEYWORDS:
Coronavirus disease 2019; Diffuse alveolar damage; Pathology; Severe acute respiratory syndrome
PMID:32241072DOI:10.3760/cma.j.cn112147-20200311-00312